Progress in controlling emesis with cancer chemotherapy

Richard J. Gralla, Rebecca A. Clark

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Marked progress in supportive care in cancer, and in control of chemotherapy-induced emesis in particular, has been accomplished over the past several years. Several effective antiemetic agents and regimens have been tested and are widely available. Emesis due to chemotherapy can now be completely controlled in the majority of patients. Progress in both clinical trials and in neuropharmacology has resulted in a new class of agents, the serotonin antagonists. These agents have an excellent therapeutic index and are well suited for a variety of clinical settings. Problems remain especially in the control of delayed emesis, in patients given several days of chemotherapy, and in radiation-induced emesis. Achieving the best antiemetic control, and at the same time having cost-effective therapy, is an ongoing challenge.

Original languageEnglish (US)
Pages (from-to)178-181
Number of pages4
JournalSupportive Care in Cancer
Volume1
Issue number4
DOIs
StatePublished - Jul 1993
Externally publishedYes

Fingerprint

Vomiting
Drug Therapy
Antiemetics
Neoplasms
Neuropharmacology
Serotonin Antagonists
Clinical Trials
Radiation
Costs and Cost Analysis
Therapeutics

Keywords

  • 5-Hydroxytryptamine receptors
  • Antiemetics
  • Serotonin antagonists

ASJC Scopus subject areas

  • Nursing(all)
  • Oncology

Cite this

Progress in controlling emesis with cancer chemotherapy. / Gralla, Richard J.; Clark, Rebecca A.

In: Supportive Care in Cancer, Vol. 1, No. 4, 07.1993, p. 178-181.

Research output: Contribution to journalArticle

@article{f2fd1c496e0a460f94d73d6e59d8aac6,
title = "Progress in controlling emesis with cancer chemotherapy",
abstract = "Marked progress in supportive care in cancer, and in control of chemotherapy-induced emesis in particular, has been accomplished over the past several years. Several effective antiemetic agents and regimens have been tested and are widely available. Emesis due to chemotherapy can now be completely controlled in the majority of patients. Progress in both clinical trials and in neuropharmacology has resulted in a new class of agents, the serotonin antagonists. These agents have an excellent therapeutic index and are well suited for a variety of clinical settings. Problems remain especially in the control of delayed emesis, in patients given several days of chemotherapy, and in radiation-induced emesis. Achieving the best antiemetic control, and at the same time having cost-effective therapy, is an ongoing challenge.",
keywords = "5-Hydroxytryptamine receptors, Antiemetics, Serotonin antagonists",
author = "Gralla, {Richard J.} and Clark, {Rebecca A.}",
year = "1993",
month = "7",
doi = "10.1007/BF00366443",
language = "English (US)",
volume = "1",
pages = "178--181",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Progress in controlling emesis with cancer chemotherapy

AU - Gralla, Richard J.

AU - Clark, Rebecca A.

PY - 1993/7

Y1 - 1993/7

N2 - Marked progress in supportive care in cancer, and in control of chemotherapy-induced emesis in particular, has been accomplished over the past several years. Several effective antiemetic agents and regimens have been tested and are widely available. Emesis due to chemotherapy can now be completely controlled in the majority of patients. Progress in both clinical trials and in neuropharmacology has resulted in a new class of agents, the serotonin antagonists. These agents have an excellent therapeutic index and are well suited for a variety of clinical settings. Problems remain especially in the control of delayed emesis, in patients given several days of chemotherapy, and in radiation-induced emesis. Achieving the best antiemetic control, and at the same time having cost-effective therapy, is an ongoing challenge.

AB - Marked progress in supportive care in cancer, and in control of chemotherapy-induced emesis in particular, has been accomplished over the past several years. Several effective antiemetic agents and regimens have been tested and are widely available. Emesis due to chemotherapy can now be completely controlled in the majority of patients. Progress in both clinical trials and in neuropharmacology has resulted in a new class of agents, the serotonin antagonists. These agents have an excellent therapeutic index and are well suited for a variety of clinical settings. Problems remain especially in the control of delayed emesis, in patients given several days of chemotherapy, and in radiation-induced emesis. Achieving the best antiemetic control, and at the same time having cost-effective therapy, is an ongoing challenge.

KW - 5-Hydroxytryptamine receptors

KW - Antiemetics

KW - Serotonin antagonists

UR - http://www.scopus.com/inward/record.url?scp=0027628850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027628850&partnerID=8YFLogxK

U2 - 10.1007/BF00366443

DO - 10.1007/BF00366443

M3 - Article

VL - 1

SP - 178

EP - 181

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 4

ER -